Phase 2 N=17 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
Atypical Hemolytic Uremic Syndrome
Primary: Platelet Count Change From Baseline to 26 Weeks — 65.18 10^9 cells/L — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=70 Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
Breast Cancer
Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF
N/A N=24 Metabolic Effects of Olanzapine in Healthy Males
Healthy
Primary: Change From Baseline in Weight — 0.2; 1.7 Kg
Phase 1 N=60 A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
Prophylaxis for the Measles Infection
Primary: Incidence of Solicited Reactions — 0; 0; 0 participants
Phase 3 N=1,114 Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Carcinoma, Hepatocellular
Primary: Recurrence Free Survival (RFS) by Independent Assessment — 1014; 1026 Days — p==0.258329
Phase 2 N=82 A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Gout Flares
Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356
N/A N=12 Investigation of a Novel Silicone Dressing to Maximize the Outcomes of Scar Revision Procedures (IMPROVE)
Hypertrophic
Primary: Visual Analogue Scale (VAS) — 3.78; 5.58 Units on a scale
N/A N=139 Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
Alcohol Dependence · Chronic Hepatitis C
Primary: The Number of Alcohol Drinks Per Week (as Measured by the Time Line Follow Back Procedure) at the 6 Month Follow-up. — 14.88; 21.41 Standard Alcohol drinks
Phase 1 N=26 Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin
Healthy
Primary: Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞) — 183; 89.4 ng*h/mL — p=1.0000
N/A N=66 Telerehabilitation Intervention to Promote Exercise for Diabetes
Diabetes Mellitus, Type 2 · Obesity
Primary: 7-Day Physical Activity Recall (PAR) — 319; 360 minutes per week
Phase 2 N=168 Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate (pCR) — 27 participants
Phase 3 N=4,758 Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
HIV-1 Infections · HIV Infections
Primary: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants — 0.65; 0.50; 1.99 events per 100 person years — p=<0.001
Phase 2 N=20 Optimization of Desflurane in Elderly Patients
Postoperative Cognitive Dysfunction
Primary: The Time From the End of Anesthesia to Extubation — 329.0; 636.0 second
N/A N=146 Mantram Repetition to Manage PTSD in Veterans
Stress Disorders, Post Traumatic
Primary: Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS) From DSM-IVTR — 83.08; 82.83; 66.16; 72.59 units on a scale — p=<0.05
Phase 4 N=99 Rehabilitation of the Stroke Hand at Home
Stroke
Primary: Action Research Arm Test (ARAT) — 39.47; 39.89 units on a scale